Attached files
| file | filename |
|---|---|
| EX-10.73 - EX-10.73 - Rich Pharmaceuticals, Inc. | ex10_73.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 1, 2017
RICH PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| NEVADA | 000-54767 | 46-3259117 | ||
(State
or other jurisdiction of |
Commission file number | (IRS Employer Identification No.) |
9595 Wilshire Blvd, Suite 900
Beverly Hills, CA 90212
(Address of principal executive offices)
(424) 230-7001
(Registrant’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ◻ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ◻ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ◻ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ◻ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 1 – Registrant’s Business and Operations
Item 1.01 Entry Into a Material Definitive Agreement
On December 1, 2017, Rich Pharmaceuticals, Inc. (the “Company”) extended the Employment Agreement for a one-year term with Ben Chang, the Company’s Chief Executive Officer. The foregoing is only a brief description of the material terms of the Employment Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements and their exhibits which are filed as an exhibit to this Current Report.
SECTION 5 – Corporate Governance and Management
Item 5.02 Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
The disclosure in Item 1.01 regarding the Employment Agreement for Ben Chang is incorporated herein by reference.
On December 1, 2017, the Board of Directors of the Company extended Ben Chang’s Employment Agreement as the Chief Executive Officer of the Company.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| No. | Description |
| 10.73 | Ben Chang Employment Extension 2017 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RICH PHARMACEUTICALS, INC. | ||||||||
| Dated: December 4, 2017 | By: | /s/ Ben Chang | ||||||
Ben Chang Chief Executive Officer | ||||||||
| 2 |